AdvaMed’s National Testing Registry: Shipments of COVID-19 Molecular Diagnostic Tests Reach 100 Million
WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) today announced that total U.S. shipments of COVID-19 molecular diagnostic tests reached approximately 100 million, as of July 25, based on the latest data from the association’s national testing registry.
“The 100-million mark represents yet another extraordinary milestone as the medical technology industry ramps up to meet the demand for testing posed by the coronavirus pandemic,” said AdvaMed president and CEO Scott Whitaker. “The diagnostics industry will continue to work 24/7, around the clock, to ensure widespread availability of test kits and supplies, doing everything possible to help beat this public health crisis.”
Unveiled July 21, AdvaMed’s Registry compiles information from diagnostics companies along with publicly available data on daily tests performed to create a centralized and standardized COVID-19 diagnostic supply registry. The registry will provide weekly state- and national-level updates on the number of molecular, antigen, and serology (antibody) tests shipped in the U.S. to help state and federal governments in their pandemic responses. AdvaMed and AdvaMedDx, the association’s division of diagnostics companies, developed the National Testing Registry in partnership with 13 commercial diagnostics manufacturers: Abbott, BD, bioMérieux, Bio-Rad, Beckman Coulter, Cepheid, Hologic, Ortho Clinical Diagnostics, QIAGEN, Roche Diagnostics, Sekisui Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific.
###
AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. AdvaMed members range from the largest to the smallest medical technology innovators and companies. For more information, visit www.advamed.org.
AdvaMedDx member companies produce innovative, safe and effective in vitro diagnostic tests that facilitate evidence-based medicine, improve quality of patient care, promote wellness, enable early detection of disease and reduce overall health care costs. Functioning as an association within AdvaMed, AdvaMedDx is dedicated to the issues facing in vitro diagnostic companies both in the United States and abroad. For more information, visit https://dx.advamed.org/